GlassScriptPhysician profile
John W Tumeh
NPI 1053540088
$8,690.35
in general payments reported to CMS, 2019-2025
34 companies · $1,629 in 2025
The $1,629 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $471 · 2020: $159 · 2021: $412 · 2022: $1,489 · 2023: $1,507 · 2024: $3,023 · 2025: $1,629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,085 · Consulting Fee: $2,040 · Education: $25.99 · Travel and Lodging: $8.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,084.75 |
| Consulting Fee | $2,040.00 |
| Education | $25.99 |
| Travel and Lodging | $8.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,840.00 | 2024 | |
| Acadia Pharmaceuticals INC | $1,256.19 | 2022-2024 | Nuplazid |
| Janssen Pharmaceuticals, INC | $889.37 | 2019-2025 | Spravato |
| Neurocrine Biosciences, INC. | $724.71 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $556.58 | 2022-2025 | Austedo Xr, Austedo, Uzedy |
| Abbvie INC. | $456.04 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $399.62 | 2021-2025 | Spravato |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $373.61 | 2022-2023 | |
| Axsome Therapeutics, INC. | $336.15 | 2023-2025 | Auvelity |
| Harmony Biosciences LLC | $216.49 | 2021-2024 | |
| Emd Serono, INC. | $186.13 | 2023-2025 | Mavenclad |
| Jazz Pharmaceuticals INC. | $181.57 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $166.83 | 2022-2025 | Qelbree |
| Otsuka America Pharmaceutical, INC. | $139.52 | 2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $138.36 | 2020-2024 | Trintellix |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $130.79 | 2024 | Kisunla |
| Corium, LLC | $108.31 | 2023-2024 | Azstarys |
| Forte Bio-Pharma LLC | $87.81 | 2025 | Tanlor |
| Lundbeck LLC | $73.76 | 2023-2024 | Rexulti |
| Tris Pharma INC | $64.16 | 2024-2025 | Dyanavel Xr |
| Idorsia Pharmaceuticals US INC | $40.31 | 2023 | Quviviq |
| Bausch Health US, LLC | $35.92 | 2024-2025 | Wellbutrin, Aplenzin |
| Neos Therapeutics, LP | $34.04 | 2024 | Adzenys Xr-Odt |
| Vanda Pharmaceuticals INC. | $30.44 | 2025 | Fanapt |
| Almatica Pharma LLC | $30.42 | 2024-2025 | Loreev Xr |
| Sunovion Pharmaceuticals INC. | $24.06 | 2022 | |
| Alkermes, INC. | $23.70 | 2021 | |
| Biogen, INC. | $23.03 | 2025 | Zurzuvae |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.02 | 2019 | |
| Collegium Pharmaceutical, INC. | $21.69 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $20.40 | 2024 | |
| Abbott Laboratories | $20.31 | 2025 | Thoratec Heartmate 3 Lvas Implant Kit |
| Owp Pharmaceuticals, INC. | $19.75 | 2024 | Subvenite |
| Bioxcel Therapeutics, INC. | $17.26 | 2024 | Igalmi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tumeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.